CANDONI, ANNA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 14.179
NA - Nord America 10.918
EU - Europa 6.208
SA - Sud America 1.610
AF - Africa 207
OC - Oceania 38
Continente sconosciuto - Info sul continente non disponibili 8
Totale 33.168
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.668
CN - Cina 5.180
SG - Singapore 3.983
HK - Hong Kong 1.768
IT - Italia 1.617
GB - Regno Unito 1.361
BR - Brasile 1.272
KR - Corea 978
VN - Vietnam 942
FI - Finlandia 897
RU - Federazione Russa 389
DE - Germania 386
SE - Svezia 344
FR - Francia 332
IN - India 249
ID - Indonesia 239
NL - Olanda 199
BD - Bangladesh 149
LT - Lituania 129
AR - Argentina 125
JP - Giappone 124
MX - Messico 112
UA - Ucraina 112
TR - Turchia 110
IQ - Iraq 100
CA - Canada 84
IE - Irlanda 69
AT - Austria 64
ZA - Sudafrica 53
EC - Ecuador 52
AE - Emirati Arabi Uniti 51
PK - Pakistan 47
BG - Bulgaria 46
ES - Italia 40
CZ - Repubblica Ceca 39
CO - Colombia 38
AU - Australia 36
PL - Polonia 35
VE - Venezuela 29
CL - Cile 28
SA - Arabia Saudita 28
UZ - Uzbekistan 28
KE - Kenya 26
EG - Egitto 25
MA - Marocco 25
PY - Paraguay 25
TW - Taiwan 24
TN - Tunisia 22
PH - Filippine 18
DZ - Algeria 17
NP - Nepal 17
TH - Thailandia 17
CH - Svizzera 16
UY - Uruguay 16
MY - Malesia 15
PT - Portogallo 15
JO - Giordania 14
PE - Perù 14
RO - Romania 14
BE - Belgio 13
IL - Israele 13
OM - Oman 13
BY - Bielorussia 11
BO - Bolivia 10
DO - Repubblica Dominicana 10
GR - Grecia 10
HN - Honduras 10
HU - Ungheria 10
DK - Danimarca 9
AZ - Azerbaigian 8
JM - Giamaica 8
KZ - Kazakistan 8
AL - Albania 7
HR - Croazia 7
PS - Palestinian Territory 7
SY - Repubblica araba siriana 7
AO - Angola 6
EU - Europa 6
KG - Kirghizistan 6
SK - Slovacchia (Repubblica Slovacca) 6
CR - Costa Rica 5
QA - Qatar 5
RS - Serbia 5
BA - Bosnia-Erzegovina 4
ET - Etiopia 4
GT - Guatemala 4
LB - Libano 4
LV - Lettonia 4
MD - Moldavia 4
MN - Mongolia 4
NO - Norvegia 4
TT - Trinidad e Tobago 4
UG - Uganda 4
BB - Barbados 3
BH - Bahrain 3
BN - Brunei Darussalam 3
CI - Costa d'Avorio 3
EE - Estonia 3
GE - Georgia 3
IR - Iran 3
Totale 33.113
Salva come PNG Salva come JPEG
Città #
Hefei 3.388
Singapore 2.415
Santa Clara 1.735
Hong Kong 1.676
Ashburn 1.438
Seoul 971
San Jose 951
Helsinki 816
London 694
Fairfield 511
The Dalles 432
Southend 381
Council Bluffs 347
Ho Chi Minh City 330
Beijing 313
Los Angeles 288
Houston 272
Woodbridge 260
Chicago 221
Lauterbourg 221
Seattle 220
Hanoi 203
Kent 196
Chandler 195
Nyköping 191
Milan 188
Jakarta 180
Wilmington 174
Ann Arbor 158
Cambridge 156
New York 148
Buffalo 134
Dallas 134
Jacksonville 130
Rome 130
São Paulo 129
Moscow 115
Dearborn 114
Munich 107
Salt Lake City 93
Shanghai 91
Amsterdam 90
Redondo Beach 81
Dublin 68
Frankfurt am Main 68
Modena 68
San Diego 67
Columbus 66
Nuremberg 62
Tokyo 60
Bologna 58
Reggio Emilia 56
Mexico City 54
Da Nang 51
Delhi 51
Elk Grove Village 50
Tampa 48
Guangzhou 44
Hillsboro 42
Princeton 40
Sofia 40
Rio de Janeiro 39
Baghdad 38
Brooklyn 38
Phoenix 38
Washington 38
Belo Horizonte 36
Izmir 35
Boston 32
Kilburn 30
Lappeenranta 30
Eugene 29
Orem 28
Florence 27
Mumbai 27
Shenzhen 27
Atlanta 26
Vienna 26
Boardman 25
Brasília 25
Curitiba 25
Haiphong 25
Johannesburg 25
Warsaw 25
Biên Hòa 24
Sterling 24
Tashkent 24
Turku 24
Guarulhos 23
Melbourne 23
Quito 23
Brno 22
Porto Alegre 22
Turin 22
Chiswick 21
Montreal 21
Tianjin 21
Des Moines 20
Dhaka 20
Miami 20
Totale 23.058
Salva come PNG Salva come JPEG
Nome #
Characterization of Specific Immune Responses to Different Aspergillus Antigens during the Course of Invasive Aspergillosis in Hematologic Patients 417
A hematology consensus agreement on antifungal strategies for neutropenic patients with hematological malignancies and stem cell transplant recipients 351
Mucorales-specific T cells in patients with hematologic malignancies 326
All-trans retinoic acid (ATRA) in patients with chronic myeloid leukemia in the chronic phase. 308
Anagrelide in Essential Thrombocythemia: A Retrospective Analysis of 220 Patients. Session Type: Poster Session 646-III 306
invasive aspergillosis in patients with acute myeloid leukemia: SEIFEM-2008 registry study. 288
Pre-chemotherapy risk factors for invasive fungal diseases: prospective analysis of 1,192 patients with newly diagnosed acute myeloid leukemia (SEIFEM 2010-a multicenter study) 286
Adolescent and young adult acute lymphoblastic leukemia. Final results of the phase II pediatric-like GIMEMA LAL-1308 trial 281
Identification and characterization of Aspergillus-specific immune responses to diagnose invasive aspergillosis in high risk patients: a multicenter study 263
Mucorles-specific T cells emerge in the course of invasive mucormucosis and may be used as a surrogate diagnostic marker in high-risk patients 259
Variability of Voriconazole Trough Levels in Haematological Patients: Influence of Comedications with cytochrome P450(CYP) Inhibitors and/or with CYP Inhibitors plus CYP Inducers 249
PEG Intron in Essential Thrombocythemia: Two Years Treatment in 90 Patients. 247
Peg Interferon alpha-2b (Peg Intron) in Essential Thrombocythemia 245
Risk stratification for invasive fungal infections in patients with hematological malignancies: SEIFEM recommendations 230
Adherence to international guidelines for the treatment of invasive aspergillosis in acute myeloid leukaemia: Feasibility and utility (SEIFEM-2008B study) 224
Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. 218
Eltrombopag for Low-Risk Myelodysplastic Syndromes With Thrombocytopenia: Interim Results of a Phase-II, Randomized, Placebo-Controlled Clinical Trial (EQOL-MDS) 215
Distribution of different classes of CSF3R mutations and co-mutational pattern in 360 myeloid neoplasia 214
Combination antifungal therapy for invasive mould diseases in haematologic patients. An update on clinical data 211
Combined antifungal approach for the treatment of invasive mucormycosis in patients with hematologic diseases: a report from the SEIFEM and FUNGISCOPE registries. 209
Breakthrough invasive fungal diseases in acute myeloid leukemia patients receiving mould active triazole primary prophylaxis after intensive chemotherapy: An Italian consensus agreement on definitions and management 207
Prognostic Relevance of Multi-Antigenic Myeloma-Specific T-Cell Assay in Patients with Monoclonal Gammopathies 205
Multicenter retrospective analysis of clinical outcome of adult patients with mixed-phenotype acute leukemia treated with acute myeloid leukemia-like or acute lymphoblastic leukemia-like chemotherapy and impact of allogeneic stem cell transplantation: a Campus ALL study 204
Liposomal amphotericin B (AmBisome®) at beginning of its third decade of clinical use 201
SEIFEM 2010-E: economic evaluation of posaconazole for antifungal prophylaxis in patients with acute myeloid leukemia receiving induction chemotherapy 199
Prospective multicenter study on infectious complications and clinical outcome of 230 unfit acute myeloid leukemia patients receiving first-line therapy with hypomethylating agents alone or in combination with Venetoclax 198
Evaluation of the practice of antifungal prophylaxis use in patients with newly diagnosed acute myeloid leukemia: results from the SEIFEM 2010-B registry. 196
Bone Marrow Evaluation According to the PVSG and WHO Criteria in 90 Essential Thrombocythemia (ET) Patients Treated with PEG Interferon alpha-2b. Preliminary Results. 190
Gimema ALL2418: Interim Analysis of a Phase Iia Study of Feasibility and Effectiveness of Inotuzumab Ozogamicin in Adult Patients with B-Cell Acute Lymphoblastic Leukemia with Positive Minimal Residual Disease before Any Hematopoietic Stem Cell Transplantation 189
PEG Intron Treatment in 90 Patients with Essential Thrombocythemia (ET) Final Report of a Phase II Study. 188
The Role of Wilms’ Tumor Gene (WT1) Expression as a Marker of Minimal Residual Disease in Acute Myeloid Leukemia 186
PEG Interferon a-2b (PEG-Intron) in Essential Thrombocythemia: Phase II Study for Determination of the Minimum Effective, Safe and Tolerated Dose. Preliminary Data. 185
Bone marrow biopsy and aspirate evaluation in 90 patients with Essential Thrombocythemia treated with PEG interferon alpha-2b. Preliminary results 184
Severe acute respiratory syndrome coronavirus 2 infection in patients with hematological malignancies in the Omicron era: Respiratory failure, need for mechanical ventilation and mortality in seronegative and seropositive patients 180
A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study 179
10-Day Decitabine Versus Intensive Chemotherapy Followed By Transplantation in Fit AML Patients Aged ≥60 Years: Health-Related Quality of Life Outcomes of the Randomized Phase III Trial AML21 of the EORTC Leukemia Group, Gimema, Celg, and Gmds-SG 177
Early palliative care versus usual haematological care in multiple myeloma: retrospective cohort study 176
Neutralizing monoclonal antibodies in haematological patients paucisymptomatic for COVID-19: The GIMEMA EMATO-0321 study 176
European Study of Cerebral Aspergillosis treated with Isavuconazole (ESCAI): A study by the ESCMID Fungal Infection Study Group 176
Up-front Blinatumomab Improves MRD Clearance and Outcome in Adult Ph− B-lineage ALL: the GIMEMA LAL2317 Phase 2 Study 175
Characteristics and clinical behavior of acute myeloid leukemia harboring rare non-A/B/D nucleophosmin (NPM1) gene mutation subtypes: a single-center experience and review of the literature 173
GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia 172
COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies 168
Multicenter Observational Retrospective Study on Febrile Events in Patients with Acute Myeloid Leukemia Treated with Cpx-351 in "Real-Life": The SEIFEM Experience 166
10-day decitabine versus 3 + 7 chemotherapy followed by allografting in older patients with acute myeloid leukaemia: an open-label, randomised, controlled, phase 3 trial 163
Infections caused by filamentous fungi in patients with hematologic malignancies. A report of 391 cases by GINEMA infection program 162
COVID-19 omicron variant outbreak in a hematopoietic stem cell transplant unit 161
Advanced mast cell disease: An Italian Hematological Multicenter experience 160
Risk of invasive fungal infection in patients affected by acute promyelocytic leukaemia. A report by the SEIFEM-D registry 158
Efficacy and safety of venetoclax plus hypomethylating agents in relapsed/refractory acute myeloid leukemia: a multicenter real-life experience 157
Sequential Chemotherapy and Blinatumomab to Improve Minimal Residual Disease in Adult Ph- B-Lineage Acute Lymphoblastic Leukemia. Final Results of the Phase II Gimema LAL2317 Trial 155
PEG Interferon alpha2b (PEG Intron) in Essential Thrombocytemia: Phase II Study for Determination of the Minimun Effective, Safe and Tolerated Dose. Preliminary Data. 153
Monitoring of minimal residual disease by quantitative WT1 gene expression following reduced intensity conditioning allogeneic stem cell transplantation in acute myeloid leukemia 152
'Real-life' analysis of the role of antifungal prophylaxis in preventing invasive aspergillosis in AML patients undergoing consolidation therapy: Sorveglianza Epidemiologica Infezioni nelle Emopatie (SEIFEM) 2016 study 151
Current epidemiology and antimicrobial resistance data for bacterial bloodstream infections in patients with hematologic malignancies: An Italian multicentre prospective survey 150
Abdominal abscess and Hafnia alvei septicemia occurring during the aplastic phase after autologous stem-cell transplantation in a patient with diffuse large B-cell lymphoma 148
Intravascular lymphoma: Clinical presentation, natural history, management and prognostic factors in a series of 38 cases, with special emphasis on the 'cutaneous variant' 148
A simple prognostic scoring system for newly diagnosed cytogenetically normal acute myeloid leukemia: Retrospective analysis of 530 patients 146
Pneumocystis jirovecii pneumonia at chest High-resolution Computed Tomography (HRCT)in non-HIV immunocompromised patients: Spectrum of findings and mimickers 146
Antibody response to mRNA vaccination for COVID-19 in patients with AML receiving hypomethylating agents alone or with venetoclax 145
Acute myeloid leukemia in patients previously diagnosed with breast cancer: Experience of the GIMEMA group 144
Preclinical Validation of an Advanced Therapy Medicinal Product Based on Cytotoxic T Lymphocytes Specific for Mutated Nucleophosmin (NPM1mut) for the Treatment of NPM1mut-Acute Myeloid Leukemia 144
Randomized comparison of liposomal amphotericin B versus placebo to prevent invasive mycoses in acute lymphoblastic leukaemia 141
Comparison between azacitidine and decitabine as front-line therapy in elderly acute myeloid leukemia patients not eligible for intensive chemotherapy 140
FLAI induction regimen in elderly patients with acute myeloid leukemia 138
Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study 138
Clinical outcome of myeloid sarcoma in adult patients and effect of allogeneic stem cell transplantation. Results from a multicenter survey 136
Identification and validation of diagnostic cut-offs of the ELISpot assay for the diagnosis of invasive aspergillosis in high-risk patients 136
Antiviral prophylaxis to prevent herpes simplex virus (HSV) and varicella zoster virus (VZV) reactivation in adult patients with newly diagnosed acute leukemia: results of a survey submitted to Italian centers belonging to SEIFEM (Sorveglianza Epidemiologica Infezioni nelle Emopatie) group 134
Pegaspargase-modified risk-oriented program for adult acute lymphoblastic leukemia: results of the GIMEMA LAL1913 trial 133
Multicentre survey to explore current survival of patients with acute myeloid leukaemia who failed induction chemotherapy 133
Azacitidine Post-Remission Therapy for Elderly Patients with AML: A Randomized Phase-3 Trial (QoLESS AZA-AMLE) 132
Antibody Binding Capacity for Evaluation of MDR-Related Proteins in Acute Promyclocytic Leukemia: Onset Versus Relapse Expression 132
INCB84344-201: Ponatinib and steroids in frontline therapy for unfit patients with Ph1 acute lymphoblastic leukemia 131
Reduced prophylactic effect of tixagevimab-cilgavimab in patients with hematological malignancies and without antibody response after SARS-COV-2 vaccination 129
Ponatinib as a Prophylactic or Pre-Emptive Strategy to Prevent Cytological Relapse after Allogeneic Stem Cell Transplantation in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Transplanted in Complete Cytological Remission 128
A 2024 Update on Menin Inhibitors. A New Class of Target Agents against KMT2A-Rearranged and NPM1-Mutated Acute Myeloid Leukemia 128
High prognostic value of pre-allogeneic stem cell transplantation minimal residual disease detection by WT1 gene expression in AML transplanted in cytologic complete remission 125
Chronic Obstructive Pulmonary Disease and Previous Infections Have Impact on Infectious Complications in Patients with Chronic Lymphocytic Leukemia Treated with Venetoclax: A Multicentre Seifem Study 124
Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in the Era of Tyrosine Kinase Inhibitors: A Registry-Based Study of the Italian Blood and Marrow Transplantation Society (GITMO) 124
Neurological complications in adult allogeneic hematopoietic stem cell transplant patients: Incidence, characteristics and long-term follow-up in a multicenter series 124
Secondary acute myeloid leukemia and early infection are independent predictors of poor survival in acute myeloid leukemia treated with hypomethylating agents and venetoclax 122
Flai (fludarabine, cytarabine, idarubicin) plus low-dose Gemtuzumab Ozogamicin as induction therapy in CD33-positive AML: Final results and long term outcome of a phase II multicenter clinical trial 122
Somatic mutations as markers of outcome after azacitidine and allogeneic stem cell transplantation in higher-risk myelodysplastic syndromes 121
18F-FDG Positron Emission Tomography (PET) Scan as a Useful Tool to Assess Response to Antimycotic Therapy in Disseminated Invasive Mycosis in Acute Myeloid Leukemia 120
Characteristics and outcome of therapy-related myeloid neoplasms: Report from the Italian network on secondary leukemias 117
A GIMEMA survey on therapeutic use and response rates of FLT3 inhibitors in acute myeloid leukemia: Insights from Italian real‐world practice 116
Prevalence and Prognostic Role of IDH Mutations in Acute Myeloid Leukemia: Results of the GIMEMA AML1516 Protocol 116
Venetoclax in combination with hypomethylating agents in previously untreated patients with acute myeloid leukemia ineligible for intensive treatment: a real-life multicenter experience 116
Anti-CD20 therapy for chronic lymphocytic leukemia-associated autoimmune diseases 116
SARS-CoV-2 infection and vaccination in patients with hairy-cell leukaemia 115
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts 115
The baseline comorbidity burden affects survival in elderly patients with acute myeloid leukemia receiving hypomethylating agents: Results from a multicentric clinical study 114
Invasive aspergillosis in relapsed/refractory acute myeloid leukaemia patients: Results from SEIFEM 2016-B survey 114
Posaconazole and midostaurin in patients with FLT3-mutated acute myeloid leukemia: Pharmacokinetic interactions and clinical facts in a real life study 113
Clinical impact of ceftazidime/avibactam on the treatment of suspected or proven infections in a large cohort of patients with haematological malignancies: a multicentre observational real-world study 113
A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study 111
Bloodstream infections caused by Klebsiella pneumoniae in onco-hematological patients: clinical impact of carbapenem resistance in a multicentre prospective survey 111
ELN2017 risk stratification improves outcome prediction when applied to the prospective GIMEMA AML1310 protocol 111
Fully oral regimen with decitabine and cedazuridine plus venetoclax: a new step forward for older or unfit patients with acute myeloid leukaemia 108
Totale 17.237
Salva come PNG Salva come JPEG
Categoria #
all - tutte 176.069
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 176.069
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021119 0 0 0 0 0 0 0 0 0 0 63 56
2021/2022729 38 101 59 44 30 57 34 42 87 52 90 95
2022/20231.245 79 47 43 53 88 87 319 130 200 28 72 99
2023/20242.253 58 67 144 201 370 187 325 230 54 65 223 329
2024/20259.165 218 117 96 624 1.549 1.063 390 347 1.016 886 1.539 1.320
2025/202617.410 1.801 1.492 2.461 2.005 1.240 1.267 2.716 854 1.550 1.661 363 0
Totale 33.544